Psychedelic Science 2023

Be Part of

        the Breakthrough

Presented by

Lessons from the first three years of psychedelic public companies

PS2023-293-tn

Lessons from the first three years of psychedelic public companies

It was not so long ago that the number of publicly-listed psychedelic businesses stood at zero. Over the last three years, numerous psychedelic drug developers and related companies have debuted on both American and Canadian exchanges, rapidly creating a multibillion dollar market. However, the path from drug discovery to approval is long, and the confidence of the market has ebbed since its peak in 2021, and much work (and fundraising) still remains to be done. Join us to hear reflections and predictions from psychedelic industry executives, investors, and analysts about the early days of psychedelic public companies.

Share: Lessons from the first three years of psychedelic public companies

Facebook
Twitter
LinkedIn
Email

Already Registered?

If you already registered for the in-person portion of the Psychedelic Science 2023 conference, get immediate access to PS2023: The Virtual Trip by logging in with the email address you used when signing up for the conference. We’ll email you a login link—no password necessary!

Need to Register?

If you are not yet registered for Psychedelic Science 2023, you can sign up for PS2023: The Virtual Trip access by creating an account.

Report an Error

The PS2023: The Virtual Trip team has worked hard to create session captions, transcripts, and web pages as accurately as possible, but we know that some errors may have made it past our review process. Let us know what needs to be fixed! Please provide the session name and/or page URL where you found the error, the time the error occurs (if in a video), and the correct information we should use to fix the error. We appreciate your help in making PS2023: The Virtual Trip even better!

Name
Hidden
This field is for validation purposes and should be left unchanged.